vTv Therapeutics Inc
VTVT14.730USD
+0.155+1.06%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
38.48MCap. mercado
PérdidaP/E TTM
Más Datos de vTv Therapeutics Inc Compañía
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its products pipeline includes TTP399, TTP273, HPP737 and HPP593. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of type I diabetes. TTP399 completed the SimpliciT-I Study, a Phase II trial in patients with type I diabetes as an add-on to insulin therapy. Its HPP737 is an orally administered, non-central nervous system (CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases. TTP273 is an orally available, small molecule glucagon-like peptide 1 (GLP-1) receptor agonist, which is focused on treating postprandial hyperglycemia in cystic fibrosis related diabetes (CFRD) patients and cystic fibrosis patients. Its products pipeline also includes Azeliragon and HPP3033.
Información de la empresa
Símbolo de cotizaciónVTVT
Nombre de la empresavTv Therapeutics Inc
Fecha de salida a bolsaJul 30, 2015
Director ejecutivoMr. Paul Jai Sekhri
Número de empleados23
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 30
Dirección3980 Premier Dr
CiudadHIGH POINT
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal27265
Teléfono13368410300
Sitio Webhttps://vtvtherapeutics.com/
Símbolo de cotizaciónVTVT
Fecha de salida a bolsaJul 30, 2015
Director ejecutivoMr. Paul Jai Sekhri
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Paul Jai Sekhri
Mr. Paul Jai Sekhri
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
5.00K
-82.80%
Dr. Srinivas Akkaraju, M.D., Ph.D.
Dr. Srinivas Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
2.25K
--
Dr. Anne M. Phillips, M.D.
Dr. Anne M. Phillips, M.D.
Independent Director
Independent Director
2.15K
--
Dr. Raymond Cheong, M.D., Ph.D.
Dr. Raymond Cheong, M.D., Ph.D.
Independent Director
Independent Director
1.83K
--
Mr. Richard S. (Rich) Nelson
Mr. Richard S. (Rich) Nelson
Executive Vice President - Corporate Development, Director
Executive Vice President - Corporate Development, Director
--
--
Mr. Fahed Al Marzooqi, M.D.
Mr. Fahed Al Marzooqi, M.D.
Independent Director
Independent Director
--
--
Mr. Burns Mcclellan
Mr. Burns Mcclellan
Investor Relations
Investor Relations
--
--
Dr. Michael Tung, M.D.
Dr. Michael Tung, M.D.
Executive Vice President, Chief Financial Officer
Executive Vice President, Chief Financial Officer
--
--
Dan Spiegelman
Dan Spiegelman
Director
Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Paul Jai Sekhri
Mr. Paul Jai Sekhri
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
5.00K
-82.80%
Dr. Srinivas Akkaraju, M.D., Ph.D.
Dr. Srinivas Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
2.25K
--
Dr. Anne M. Phillips, M.D.
Dr. Anne M. Phillips, M.D.
Independent Director
Independent Director
2.15K
--
Dr. Raymond Cheong, M.D., Ph.D.
Dr. Raymond Cheong, M.D., Ph.D.
Independent Director
Independent Director
1.83K
--
Mr. Richard S. (Rich) Nelson
Mr. Richard S. (Rich) Nelson
Executive Vice President - Corporate Development, Director
Executive Vice President - Corporate Development, Director
--
--
Mr. Fahed Al Marzooqi, M.D.
Mr. Fahed Al Marzooqi, M.D.
Independent Director
Independent Director
--
--
Desglose de ingresos
FY2023
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
United States
0.00
0.00%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: vie., 16 de may
Actualizado: vie., 16 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
MacAndrews & Forbes Holdings, Inc.
34.88%
Samsara BioCapital, LLC
7.90%
Fidelity Management & Research Company LLC
6.81%
Baker Bros. Advisors LP
3.72%
The Vanguard Group, Inc.
1.59%
Other
45.10%
Accionistas
Accionistas
Proporción
MacAndrews & Forbes Holdings, Inc.
34.88%
Samsara BioCapital, LLC
7.90%
Fidelity Management & Research Company LLC
6.81%
Baker Bros. Advisors LP
3.72%
The Vanguard Group, Inc.
1.59%
Other
45.10%
Tipos de accionistas
Accionistas
Proporción
Holding Company
34.88%
Investment Advisor
8.96%
Venture Capital
7.90%
Hedge Fund
4.09%
Investment Advisor/Hedge Fund
1.09%
Individual Investor
0.72%
Other
42.35%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
54
1.51M
57.65%
-16.72K
2025Q1
53
1.53M
60.03%
+1.63K
2024Q4
55
1.51M
61.92%
-7.51K
2024Q3
55
1.49M
61.31%
+181.69K
2024Q2
53
1.29M
53.13%
+308.00
2024Q1
64
1.68M
72.07%
+129.32K
2023Q4
64
1.40M
68.78%
-52.49K
2023Q3
72
1.41M
69.35%
-49.61K
2023Q2
81
1.40M
81.32%
+323.67K
2023Q1
107
1.40M
81.41%
+294.71K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
MacAndrews & Forbes Holdings, Inc.
912.98K
34.88%
--
--
Apr 01, 2025
Samsara BioCapital, LLC
206.78K
7.9%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
178.20K
6.81%
--
--
Mar 31, 2025
Baker Bros. Advisors LP
97.31K
3.72%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
41.56K
1.59%
--
--
Mar 31, 2025
Northern Trust Investments, Inc.
15.63K
0.6%
+15.63K
--
Mar 31, 2025
Geode Capital Management, L.L.C.
12.64K
0.48%
+1.00K
+8.62%
Mar 31, 2025
Connective Capital Management, LLC
9.38K
0.36%
+9.38K
--
Mar 31, 2025
Sekhri (Paul Jai)
5.00K
0.19%
-24.06K
-82.80%
Apr 01, 2025
Northern Trust Global Investments
4.71K
0.18%
-194.00
-3.96%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Micro-Cap ETF
0.01%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Micro-Cap ETF
Proporción0.01%
iShares Core S&P Total U.S. Stock Market ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Nov 15, 2023
Merger
40<1
Nov 15, 2023
Merger
40<1
Nov 15, 2023
Merger
40<1
Nov 15, 2023
Merger
40<1
Fecha
Tipo
Relación
Nov 15, 2023
Merger
40<1
Nov 15, 2023
Merger
40<1
Nov 15, 2023
Merger
40<1
Nov 15, 2023
Merger
40<1
